Last reviewed · How we verify
Lifitegrast 5% Ophthalmic Solution
Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist that blocks T-cell adhesion and infiltration into ocular tissues to reduce inflammation in dry eye disease.
Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist that blocks T-cell adhesion and infiltration into ocular tissues to reduce inflammation in dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | Lifitegrast 5% Ophthalmic Solution |
|---|---|
| Also known as | Xiidra, Xiidra 5% Ophthalmic Solution |
| Sponsor | Research Insight LLC |
| Drug class | LFA-1 antagonist |
| Target | LFA-1 (lymphocyte function-associated antigen-1) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Lifitegrast selectively inhibits LFA-1, an integrin expressed on lymphocytes, preventing their adhesion to intercellular adhesion molecule-1 (ICAM-1) on ocular surface cells. This blocks T-cell migration and infiltration into the eye, reducing the inflammatory cascade that characterizes dry eye disease. By decreasing lymphocyte-mediated inflammation at the ocular surface, the drug alleviates symptoms and improves tear production.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Instillation site irritation
- Dysgeusia (taste perversion)
- Ocular discomfort
- Conjunctival hyperemia
Key clinical trials
- Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (PHASE4)
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (PHASE1, PHASE2)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers (PHASE4)
- An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber (PHASE2)
- Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers (PHASE4)
- The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lifitegrast 5% Ophthalmic Solution CI brief — competitive landscape report
- Lifitegrast 5% Ophthalmic Solution updates RSS · CI watch RSS
- Research Insight LLC portfolio CI